Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Prepaid Assets: 2019-2024

Historic Prepaid Assets for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $10.9 million.

  • Allogene Therapeutics' Prepaid Assets fell 33.66% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 33.66%. This contributed to the annual value of $10.9 million for FY2024, which is 4.72% up from last year.
  • Per Allogene Therapeutics' latest filing, its Prepaid Assets stood at $10.9 million for FY2024, which was up 4.72% from $10.4 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Prepaid Assets registered a high of $17.2 million during FY2020, and its lowest value of $10.4 million during FY2023.
  • For the 3-year period, Allogene Therapeutics' Prepaid Assets averaged around $10.9 million, with its median value being $10.9 million (2024).
  • In the last 5 years, Allogene Therapeutics' Prepaid Assets rose by 22.62% in 2020 and then fell by 18.58% in 2021.
  • Over the past 5 years, Allogene Therapeutics' Prepaid Assets (Yearly) stood at $17.2 million in 2020, then declined by 18.58% to $14.0 million in 2021, then decreased by 17.95% to $11.5 million in 2022, then declined by 9.44% to $10.4 million in 2023, then increased by 4.72% to $10.9 million in 2024.